Several institutional investors have adjusted their positions in Moderna during the first and fourth quarters of 2025.
ABC Arbitrage SA initiated a new position, purchasing 54,198 shares valued at approximately $1.5 million.&ref=yanuki.com
LPL Financial LLC increased its stake by 83.8%, acquiring an additional 308,334 shares.&ref=yanuki.com
Envestnet Asset Management Inc. reduced its holdings by 40.3%, selling 12,212 shares.&ref=yanuki.com
Overall, institutional investors hold 75.33% of Moderna's stock.&ref=yanuki.com
Analyst ratings are mixed, with a consensus rating of "Hold" and an average price target of $45.61.&ref=yanuki.com
Why does this matter? Institutional investor activity can significantly influence stock prices. Monitoring these transactions can provide insights into the long-term prospects of Moderna and the confidence institutional players have in the company.
Moderna, Inc. (NASDAQ:MRNA) has seen considerable activity from institutional investors recently. These transactions provide a glimpse into how major investment firms view the company's potential.
Notable Transactions:
ABC Arbitrage SA:: Took a new position in Moderna, purchasing 54,198 shares valued at around $1.5 million.&ref=yanuki.com
LPL Financial LLC:: Significantly increased its stake by 83.8%, acquiring 308,334 shares. Now owns 676,212 shares valued at $19.171 million.&ref=yanuki.com
Envestnet Asset Management Inc.:: Reduced its position by 40.3%, selling 12,212 shares. Remaining holdings are 18,102 shares valued at $513,000.&ref=yanuki.com
FMR LLC:: Increased its stake by 7.4% during Q4, now owning 18,664,634 shares valued at $776.075 million.&ref=yanuki.com
Invesco Ltd.:: Increased its stake by 24.3% during Q4, now holding 5,006,462 shares valued at $208.169 million.&ref=yanuki.com
Analyst Ratings:
Analysts have a mixed view of Moderna. The consensus rating is "Hold," with an average price target of $45.61. Recent reports include:
Citigroup:: Initiated coverage with a "Neutral" rating and a $40 price target.&ref=yanuki.com
Royal Bank of Canada:: Cut their price target from $32 to $28, maintaining a "Sector Perform" rating.&ref=yanuki.com
UBS Group:: Decreased their price objective from $78 to $70, keeping a "Buy" rating.&ref=yanuki.com
Moderna's stock opened at $27.64 on Tuesday and has a market cap of $10.69 billion. The stock's 50-day moving average is $29.22, and its 200-day moving average is $30.24. Institutional investors and hedge funds own 75.33% of the company's stock, indicating strong institutional interest.&ref=yanuki.com
Q: What percentage of Moderna stock is owned by institutional investors?
Institutional investors and hedge funds own 75.33% of Moderna's stock.&ref=yanuki.com
Q: What is the average analyst rating for Moderna?
Moderna has an average rating of "Hold" among analysts.&ref=yanuki.com
Q: What was Moderna's revenue for the last quarter?
Moderna reported revenue of $142.00 million for the quarter.&ref=yanuki.com
Institutional investor activity provides insights into market sentiment regarding Moderna.
A significant percentage of Moderna's stock is held by institutional investors, indicating strong interest from major players.
Analyst ratings are mixed, suggesting a cautious approach to the stock.
Do you think institutional investment activity is a reliable indicator of Moderna's future performance? Share your thoughts in the comments below!
Share this article with others who need to stay ahead of this trend!
Robinhood Markets, Inc. saw its stock value increase following the release of its second-quarter earnings report, driven by a surge in crypt...
This article summarizes recent institutional investment activities and analyst ratings concerning Ford Motor Company (NYSE:F) as of July 202...
Lucid Group (NASDAQ: LCID) has announced plans for a 1-for-10 reverse stock split, aiming to boost its stock appeal to a broader investor ba...
Recent SEC filings reveal shifts in institutional investor positions in Xcel Energy Inc. (NASDAQ:XEL), reflecting evolving sentiment towards...
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer